A carregar...
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated pati...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4283628/ https://ncbi.nlm.nih.gov/pubmed/25601865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2014.00668 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|